J&J to pay $181 million for Risperdal settlement

Share this article:
J&J to pay $181 million for Risperdal settlement
J&J to pay $181 million for Risperdal settlement
Janssen Pharmaceuticals, a unit of Johnson & Johnson, will pay $181 million to settle charges that it marketed antipsychotic medications for medically unapproved purposes.
 
The payouts will go to 36 states, plus the District of Columbia, which brought consumer fraud charges against Janssen for allegedly deceptively marketing the drug Risperdal to providers treating patients with Alzheimer's and dementia, Reuters reported. The drug, which is intended to treat schizophrenia, is not approved for these conditions.
 
Although it is legal for physicians to prescribe drugs such as Risperdal for unapproved indications, manufacturers are forbidden from promoting the drug to providers for such uses. Risperdal often is used in nursing homes to sedate agitated memory care residents. Regulators and provider groups have been working to reduce this practice.

J & J has been involved in several multimillion-dollar settlements with regard to Risperdal in recent months. In March, federal prosecutors rejected a $1 billion settlement with J & J over Risperdal.
Share this article:

More in News

White House creates new national strategy on antibiotics

White House creates new national strategy on antibiotics

The Obama administration has unveiled a national strategy to combat antibiotic-resistant bacteria. It includes an executive order to direct the federal government to "reduce the emergence and spread of antibiotic-resistant ...

Medicaid provider agreement remains legitimate during bankruptcy proceedings, judge rules

Medicaid must continue to make payments to a Florida nursing home undergoing bankruptcy proceedings, a federal judge rule recently.

Legislator pushes for more HCBS services for Medicaid beneficiaries

Medicaid beneficiaries would have an opportunity to receive more care in a home or community-based setting if a House of Representatives bill passes.